

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CEPHALON, INC.,)	
)	
Plaintiff,)	
)	
v.)	C.A. No. _____
)	
HOSPIRA INC.,)	
Defendant.)	

COMPLAINT

Cephalon, Inc. (“Cephalon” or “Plaintiff”) brings this action for patent infringement against Defendant Hospira Inc. (“Hospira” or “Defendant”).

1. This is an action by Cephalon against Hospira for infringement of United States Patent No. 8,791,270 (“the ’270 patent”). This action arises out of Hospira’s filing of an Abbreviated New Drug Application (“ANDA”) seeking approval by the United States Food and Drug Administration (“FDA”) to sell generic versions of TREANDA[®], Cephalon’s innovative treatment for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, prior to the expiration of the ’270 patent.

THE PARTIES

Cephalon, Inc.

2. Plaintiff Cephalon, Inc. is a corporation operating and existing under the laws of Delaware, with its principal place of business at 41 Moores Road, Frazer, Pennsylvania 19355. Cephalon is engaged in the business of research, development, manufacture, and sale of innovative pharmaceutical products throughout the world.

Hospira Inc.

3. On information and belief, Defendant Hospira is a corporation organized under the laws of Delaware, with its principal place of business at 275 North Field Dr., Lake Forest, Illinois 60045.

JURISDICTION AND VENUE

Subject Matter Jurisdiction

4. This action for patent infringement arises under 35 U.S.C. § 271.

5. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a), and the Declaratory Judgment Act, 28 U.S.C §§ 2201 and 2202.

Personal Jurisdiction Over Hospira

6. On information and belief, this Court has personal jurisdiction over Hospira at least because Hospira: (1) is incorporated in Delaware, (2) conducts business in this Judicial District and (3) has engaged in continuous and systematic contacts with Delaware and/or purposefully availed itself of this forum by, among other things, making, shipping, using, offering to sell or selling, or causing others to use, offer to sell, or sell, Hospira pharmaceutical products in this Judicial District, and deriving substantial revenue from such activities. On information and belief, Hospira has also committed, or aided, abetted, contributed to and/or participated in the commission of, the tortious action of patent infringement that has led to foreseeable harm and injury to Cephalon, which manufactures TREANDA[®], for sale and use throughout the United States, including the State of Delaware. Also, on information and belief, Hospira maintains a Pharmacy Wholesale License in the State Delaware.

7. On information and belief, this Court also has personal jurisdiction over Hospira because Hospira previously has availed itself of this forum for the purpose of litigating its patent

infringement disputes. *See Hospira Inc. v. B. Braun Medical Inc.*, C.A. No. 13-819 (D. Del.); *Hospira Inc. et al v. Sandoz International GmbH et al*, C.A. No. 09-665 (D. Del.).

8. On information and belief, this Court also has personal jurisdiction over Hospira because Hospira did not challenge this Court's exercise of personal jurisdiction over it for purposes of litigating allegations of patent infringement involving the ANDA that is the subject matter of this lawsuit. *See Cephalon, Inc. v. Hospira Inc.*, C.A. No. 13-2094 (D. Del.).

Venue

9. Venue is proper in this Judicial District under 28 U.S.C. §§ 1391 and 1400(b).

BACKGROUND

The '270 Patent

10. The '270 patent, entitled "Bendamustine Pharmaceutical Compositions," was duly and lawfully issued on July 29, 2014 to inventors Jason E. Brittain and Joe C. Franklin.

11. The named inventors of the '270 patent assigned their rights in the '270 patent to Cephalon.

12. Cephalon is the sole owner by assignment of all rights, title and interest in the '270 patent.

13. Shortly after the '270 patent issued, Cephalon listed the '270 patent in FDA publication "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly referred to as "the Orange Book" ("Orange Book") with respect to TREANDA[®].

14. The '270 patent will expire on January 12, 2026. A true and accurate copy of the '270 patent is attached hereto as Exhibit A.

The TREANDA[®] Drug Product

15. Cephalon researched, developed, applied for and obtained FDA approval to manufacture, sell, promote and/or market bendamustine hydrochloride products known as TREANDA[®].

16. Cephalon has been selling, promoting, distributing and marketing TREANDA[®] in the United States since 2008.

17. TREANDA[®] is indicated to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

18. Cephalon holds New Drug Application No. 22249 and No. 22303 under Section 505(a) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a), for multiple TREANDA[®] products used for treating chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

The Hospira ANDA

19. Hospira filed with FDA an Abbreviated New Drug Application under 21 U.S.C. § 355(j)(1) seeking approval to manufacture, use, offer for sale, sell in and import into the United States bendamustine hydrochloride for injection, 25 mg/vial and 100 mg/vial ("Hospira's Bendamustine Product") prior to the expiration of the '270 patent.

20. FDA assigned the ANDA for Hospira's Bendamustine Product the number 204086.

The Ongoing Litigation

21. In connection with its ANDA, Hospira filed with FDA, pursuant to 21 U.S.C. § 355(j)(2)(B)(iv), a certification alleging that the claims of other Cephalon patents, of United States Patent No. 8,445,524 ("the '524 patent") and United States Patent No. 8,436,190 ("the

'190 patent"), are invalid, unenforceable and/or would not be infringed by the manufacture, use, importation, sale or offer for sale of Hospira's Bendamustine Product ("Hospira's Paragraph IV Certification").

22. By letter dated November 19, 2013, Hospira notified Cephalon that it had filed ANDA No. 204086 seeking approval to market Hospira's Bendamustine Product prior to the expiration of the '524 patent and the '190 patent ("Hospira Notice Letter").

23. On December 18, 2013, pursuant to an Offer of Confidential Access, Cephalon received portions of the ANDA filed by Hospira, and Cephalon reviewed those portions of the ANDA.

24. On December 26, 2013, Cephalon sued Hospira for patent infringement of the '524 patent and the '190 patent in the District of Delaware. *See Cephalon, Inc. v. Hospira Inc.*, C.A. No. 13-2094 (D. Del.). That action was commenced before the expiration of forty-five days from the date of receipt of the Hospira Notice Letter, which effectively stayed FDA from granting final approval to Hospira's ANDA No. 204086 prior to the expiration of 30 months from the date the Hospira Notice Letter was received by Cephalon.

COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,791,270 BY HOSPIRA

25. The allegations of the preceding paragraphs 1–24 are re-alleged and incorporated herein by reference.

26. The '270 patent issued on July 29, 2014, and Cephalon timely listed the '270 patent in the Orange Book.

27. Cephalon notified Hospira of the issuance of the '270 patent before filing this action.

28. The use of Hospira's Bendamustine Product is covered by one or more claims of the '270 patent.

29. The commercial manufacture, use, offer for sale, sale, marketing, distribution and/or importation of Hospira's Bendamustine Product would infringe one or more claims of the '270 patent.

30. Under 35 U.S.C. § 271(e)(2)(A), Hospira's submission to FDA of the Hospira ANDA to obtain approval for Hospira's Bendamustine Product before the expiration of the '270 patent constitutes an act of infringement, and if approved, the commercial manufacture, use, offer to sell, sale, or importation of Hospira's Bendamustine Product containing bendamustine hydrochloride, would infringe one or more claims of the '270 patent.

31. On information and belief, Hospira's Bendamustine Product contains the same active pharmaceutical ingredient, bendamustine hydrochloride, as that used in Cephalon's TREANDA[®] products and claimed in the '270 patent.

32. On information and belief, Hospira's Bendamustine Product is the pharmaceutical composition of bendamustine hydrochloride, containing less than or equal to 4.0% (area percent of bendamustine) of bendamustine degradants, recited in one or more claims of the '270 patent.

33. On information and belief, Hospira's Bendamustine Product is the pharmaceutical composition of bendamustine hydrochloride, containing not more than the amount of the HP1 degradant, recited in one or more claims of the '270 patent.

34. On information and belief, Hospira's Bendamustine Product infringes one or more claims of the '270 patent.

35. On information and belief, Hospira plans and intends to, and will, infringe the '270 patent immediately and imminently upon approval of the Hospira ANDA.

36. On information and belief, Hospira, under 35 U.S.C. § 271(b), acted in concert, actively supported, participated in, encouraged, and/or induced the infringement of one or more claims of the '270 patent.

37. On information and belief, Hospira plans and intends to, and will, actively induce infringement of the '270 patent when the Hospira ANDA is approved, and plan and intend to, and will, do so immediately and imminently upon approval.

38. On information and belief, Hospira knows that Hospira's Bendamustine Product is especially made or adapted for use in infringing the '270 patent and that Hospira's Bendamustine Product is not suitable for substantial non-infringing uses. On information and belief, under 35 U.S.C. § 271(c), Hospira plans and intends to, and will, contribute to the infringement of the '270 patent immediately and imminently upon approval of the Hospira ANDA.

39. The foregoing actions by Hospira constitute and/or would constitute infringement of the '270 patent, active inducement of infringement of the '270 patent and/or contribution to the infringement by others of the '270 patent.

40. On information and belief, Hospira acted without a reasonable basis for believing that it would not be liable for infringing the '270 patent, actively inducing infringement of the '270 patent and/or contributing to the infringement by others of the '270 patent.

41. Cephalon will be substantially and irreparably harmed by Hospira's infringing activities unless the Court enjoins those activities. Cephalon will have no adequate remedy at law if Hospira is not enjoined from the commercial manufacture, use, offer to sell, sale in and importation into the United States of Hospira's Bendamustine Product.

42. Hospira's activities render this case an exceptional one, and Cephalon is entitled to an award of its reasonable attorneys' fees under 35 U.S.C. § 285.

**COUNT II DECLARATORY JUDGMENT OF
INFRINGEMENT OF U.S. PATENT NO. 8,791,270 BY HOSPIRA**

43. The allegations of the proceeding paragraphs 1–42 are re-alleged and incorporated herein by reference.

44. On information and belief, Hospira plans to begin manufacturing, marketing, selling, offering to sell and/or importing Hospira's Bendamustine Product soon after FDA approval of the Hospira NDA.

45. Such conduct will constitute direct infringement of one or more claims on the '270 patent under 35 U.S.C. § 271(a), inducement of infringement of the '270 patent under 35 U.S.C. § 271(b), and contributory infringement under 35 U.S.C. § 271(c).

46. Hospira's infringing patent activity complained of herein is imminent and will begin following FDA approval of the Hospira NDA.

47. As a result of the foregoing facts, there is a real, substantial, and continuing justiciable controversy between Cephalon and Hospira as to liability for the infringement of the '270 patent. Hospira's actions have created in Cephalon a reasonable apprehension of irreparable harm and loss resulting from Hospira's threatened imminent actions.

48. On information and belief, Hospira will knowingly and willfully infringe the '270 patent.

49. Cephalon will be substantially and irreparably harmed by Hospira's infringing activities unless the Court enjoins those activities.

PRAYER FOR RELIEF

WHEREFORE, Cephalon respectfully requests the following relief:

- a. a judgment that the '270 patent is valid and enforceable;
- b. a judgment that Hospira's submission of the Hospira ANDA No. 204086 was an act of infringement of one or more claims of the '270 patent and that the making, using, offering to sell, selling, marketing, distributing, or importing of Hospira's Bendamustine Products prior to the expiration of the '270 patent will infringe, actively induce infringement and/or contribute to the infringement of one or more claims of the '270 patent;
- c. an Order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any FDA approval of the Hospira ANDA No. 204086 or any product or compound the use of which infringes the '270 patent shall be a date that is not earlier than the expiration of the '270 patent;
- d. an Order pursuant to 35 U.S.C. § 271(e)(4)(B) permanently enjoining Hospira and all persons acting in concert with Hospira from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing Hospira's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or inducing or contributing to the infringement of the '270 patent, until after the expiration of the '270 patent;
- e. an Order pursuant to 35 U.S.C. § 283 permanently enjoining Hospira and all persons acting in concert with Hospira from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing Hospira's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or inducing or contributing to the infringement of the '270 patent, until after the expiration of the '270 patent;

f. an Order enjoining Hospira and all persons acting in concert with Hospira from seeking, obtaining, or maintaining approval of the Hospira ANDA No. 204086 before the expiration of the '270 patent;

g. an award of Cephalon's damages or other monetary relief to compensate Cephalon if Hospira engages in the commercial manufacture, use, offer to sell, sale or marketing or distribution in, or importation into the United States of Hospira's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or the inducement or contribution of the foregoing, prior to the expiration of the '270 patent in accordance with 35 U.S.C. § 271(e)(4)(C);

h. an award of Cephalon's damages or other monetary relief to compensate Cephalon if Hospira engages in the commercial manufacture, use, offer to sell, sale or marketing or distribution in, or importation into the United States of Hospira's Bendamustine Products, or any product or compound the use of which infringes the '270 patent, or the inducement or contribution of the foregoing, prior to the expiration of the '270 patent;

i. a judgment that this is an exceptional case and awarding Cephalon its attorneys' fees under 35 U.S.C. § 285;

j. an award of Cephalon's reasonable costs and expenses in this action; and

k. an award of any further and additional relief to Cephalon as this Court deems just and proper.

Respectfully submitted,

/s/ John W. Shaw

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
SHAW KELLER LLP
300 Delaware Ave., Suite 1120
Wilmington, DE 19801
(302) 298-0700

jshaw@shawkeller.com
kkeller@shawkeller.com

Attorneys for Plaintiff Cephalon, Inc.

OF COUNSEL:

David M. Hashmall
Calvin E. Wingfield Jr.
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
(212) 813-8800

Daryl L. Wiesen
Emily L. Rapalino
Nicholas K. Mitrokostas
Exchange Place
Boston, MA 02109
(617) 570-1000

Dated: September 26, 2014